DI-Leu16-IL2

DRUG2 trials

Sponsors

Alopexx Oncology, LLC

Conditions

B-cell Non-Hodgkin Lymphoma

Phase 1

A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL

TerminatedNCT01874288

Alopexx Oncology, LLCB-cell Non-Hodgkin Lymphoma

Start: 2013-11-25End: 2016-11-16Updated: 2020-11-24

Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL

TerminatedNCT02151903

Alopexx Oncology, LLCB-cell Non-Hodgkin Lymphoma

Start: 2014-11-04End: 2016-07-11Updated: 2020-11-27

Related Papers

DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose

Blood2016-12-0220 citations

Phase I/II study of an anti-CD20-interleukin-2 immunocytokine DI-Leu16-IL2 in patients with relapsed b-cell lymphoma (NHL).

Journal of Clinical Oncology2016-05-209 citations

Remission Induction in a Phase I/II Study of an Anti-CD20-Interleukin-2 Immunocytokine DI-Leu16-IL2 in Patients with Relapsed B-Cell Lymphoma

Blood2015-12-0317 citations